BLI1100-1

BLI1100-1 is an investigational topical gel formulation developed by Braintree Laboratories (now a subsidiary of Sebela Pharmaceuticals) for the treatment of moderate to severe acne vulgaris. It was evaluated in a Phase 2 randomized, controlled clinical trial (NCT01644435) that compared four distinct formulations of the drug (BLI1100-1, BLI1100-2, BLI1100-3, and BLI1100-4) against a placebo. The trial, completed in 2013, assessed the safety and efficacy of the treatment based on the reduction of inflammatory and non-inflammatory lesion counts and Investigator's Global Assessment (IGA) scores. Although the clinical development reached Phase 2, the specific active pharmaceutical ingredient and its biological target have not been disclosed in public literature or clinical trial registries.